Imbruvica 140 mg | Imbruvica capsules 140 mg |
Apple Pharmacy
Imbruvica 140 mg | Imbruvica capsules 140 mg | Ibrutinib 140 mg | Ibrutinib Capsules 140 mg |
Apple, pharmaceuticals
Apple, pharmaceuticals
Imbruvica capsules 140 mg ( Ibrutinib 140 mg )
 |
| ibutinib |
IMBRUVICA stops the protein in B cells, called Bruton tyrosine kinase, or BTK. Indication of BTK is required for B cells to multiply and survive.
By inhibiting BTK, Imbruvica 140 mg can help the progress of abnormal B cells from their culture media in the lymph nodes, bone marrow, and other organs.
Imbruvica is a prescription drug that is used under the guidance of healthcare providers.
By inhibiting BTK, Imbruvica 140 mg can help the progress of abnormal B cells from their culture media in the lymph nodes, bone marrow, and other organs.
Imbruvica is a prescription drug that is used under the guidance of healthcare providers.
INDICATIONS
 |
| capsules |
Imbruvica 140 mg is indicated for the treatment of the following condition:
•Manto-cell lymphoma (MCL), which receive at least one before treatment
• Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (CLL)
• Chronic lymphocytic leukemia (CLL) / Minor lymphocytic lymphoma (CLL) with 17p deletions • Waldenstrom macroglobulinemia (WM)
• Marginal area lymphoma (MZL), which is given either orally or by injection (systemic therapy) and is given a certain type before treatment
• Chronic graft versus host disease (cGVHD) after abandoning 1 or more lines of systemic therapy
•Manto-cell lymphoma (MCL), which receive at least one before treatment
• Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (CLL)
• Chronic lymphocytic leukemia (CLL) / Minor lymphocytic lymphoma (CLL) with 17p deletions • Waldenstrom macroglobulinemia (WM)
• Marginal area lymphoma (MZL), which is given either orally or by injection (systemic therapy) and is given a certain type before treatment
• Chronic graft versus host disease (cGVHD) after abandoning 1 or more lines of systemic therapy
one
The peak concentration of Imbruvica in plasma is 1-2 hours, and taking medication with food increases the effects of ibrutinib .
Imbruvica has plasma protein level is 97.3% and Vd is 10,000L
Ibrutinib is Metabolized to various metabolites primarily by cytochrome P450 CYP3A, and to a minor extent by CYP2D6
Ibrutinib was excretion through feces 80% and urine 10 % Half-life of ibrutinib is 4-6 hours
Imbruvica has plasma protein level is 97.3% and Vd is 10,000L
Ibrutinib is Metabolized to various metabolites primarily by cytochrome P450 CYP3A, and to a minor extent by CYP2D6
Ibrutinib was excretion through feces 80% and urine 10 % Half-life of ibrutinib is 4-6 hours
DOSAGE
 |
| Imbruvica 140mg |
Chronic Lymphocytic Leukaemia/Small Lymphocytic
Lymphoma:
The recommended dose of patient is 420mg (three 140mg capsules) per oral qday
While in combination with bendamustine and rituximab the usual dose is 420mg PO qDay administrated q28d for up to 6 cycles until progression or undesirable toxicity
Mantle Cell Lymphoma:
The recommended dose of patientis 560mg (four 140mg-mg capsules) PO qDay.
Follow until disease progression or undesirable toxicity
Waldenström Macroglobulinemia :
The recommended dose of patient is 420mg (three 140mg capsules) per oral qDay
When combination with rituximab is 420 mg PO qDay plus rituximab administered weekly for 4 consecutive weeks (weeks 1-4)
continued by a second course of weekly rituximab for 4 consecutive weeks (weeks 17-20)
Marginal Zone Lymphoma :
The recommended dose of patientis 560mg (four 140mg-mg capsules) PO qDay.
Follow until disease progression or undesirable toxicity
Graft vs Host Disease:
The recommended dose of patient is 420mg (three 140mg capsules) per oral qDay
Follow until cGVHD progression, recurrence of an underlying malignancy, or undesirable toxicity occurs
The recommended dose of patient is 420mg (three 140mg capsules) per oral qday
While in combination with bendamustine and rituximab the usual dose is 420mg PO qDay administrated q28d for up to 6 cycles until progression or undesirable toxicity
Mantle Cell Lymphoma:
The recommended dose of patientis 560mg (four 140mg-mg capsules) PO qDay.
Follow until disease progression or undesirable toxicity
Waldenström Macroglobulinemia :
The recommended dose of patient is 420mg (three 140mg capsules) per oral qDay
When combination with rituximab is 420 mg PO qDay plus rituximab administered weekly for 4 consecutive weeks (weeks 1-4)
continued by a second course of weekly rituximab for 4 consecutive weeks (weeks 17-20)
Marginal Zone Lymphoma :
The recommended dose of patientis 560mg (four 140mg-mg capsules) PO qDay.
Follow until disease progression or undesirable toxicity
Graft vs Host Disease:
The recommended dose of patient is 420mg (three 140mg capsules) per oral qDay
Follow until cGVHD progression, recurrence of an underlying malignancy, or undesirable toxicity occurs
MECHANISM
 |
| cheer up |
Ibrutinib 140mg belongs to type of small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a indicating molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK's role in indicating via the B-cell surface receptors reports in activation of pathways required for B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies revealwhich ibrutinib prohibits malignant B-cell multiplication and survival in vivo as well as cell migration and substrate adhesion in vitro.
PRECAUTION
Other malignancies (5-14%) resulted contains carcinomas (1-3%); the most frequent second primary malignancy was nonmelanoma skin cancer (4-11%)
Hypertension occurs with a median time to onset of 4.6 months; regulate for new onset hypertension or hypertension that is not sufficient controlled after starting ibrutinib
Tumor lysis syndrome intermittentlyresulted; assess the baseline risk (eg, high tumor burden) and take suitable precautions
Based on findings in animals, can cause fetal risk when administered to a pregnant woman
Fatal and severe cases of renal failure resulted; treatment-emergent have high in creatinine levels up to 1.5 x ULN occurred in 67% (MCL) and 23% (CLL) and from 1.5-3x ULN in 9% (MCL) and 4% (CLL); regularly monitor creatinine and maintain hydration
Hypertension occurs with a median time to onset of 4.6 months; regulate for new onset hypertension or hypertension that is not sufficient controlled after starting ibrutinib
Tumor lysis syndrome intermittentlyresulted; assess the baseline risk (eg, high tumor burden) and take suitable precautions
Based on findings in animals, can cause fetal risk when administered to a pregnant woman
Fatal and severe cases of renal failure resulted; treatment-emergent have high in creatinine levels up to 1.5 x ULN occurred in 67% (MCL) and 23% (CLL) and from 1.5-3x ULN in 9% (MCL) and 4% (CLL); regularly monitor creatinine and maintain hydration
DRUG INTERACTION
 |
| Drug |
When Co administration of imbruvica 140 mg with a strong or moderate CYP3A inhibitor increases plasma concentrations of ibrutinib along with a high risk of drug-related toxicity
When Co administration of imbruvica 140 mg with strong or moderate inducers of CYP3A will decrease plasma concentrations of ibrutinib .
CONTRAINDICATIONS
Hypersensitivity reaction
Missed dose
If a dose is missed, then the missed dose should be avoided and the regular dosing schedule should be observed. Patients should consult a physician and follow the instructions given by them.
SIDE EFFECTS
 |
| by-effect |
• Low platelets
• musculoskeletal pain
• edema
• upper respiratory tract infection
• nausea
• diarrhea
• Reduced neutrophils
• Hemoglobin reduction
• fatigue
• Bruises.
• musculoskeletal pain
• edema
• upper respiratory tract infection
• nausea
• diarrhea
• Reduced neutrophils
• Hemoglobin reduction
• fatigue
• Bruises.
• skin infections
• Asthenia
• Muscle spasms
• confused breathing
Constipation
• rash
• sinusitis
• Headache
• Dehydration
• dyspepsia
• Abdominal pain
• vomiting
• loss of appetite
• cough
• fever
• stomatitis
• dizziness
• Urinary tract infection
• Pneumonia
• petechiae
• Arthralgia
• Nose bleed.
• Asthenia
• Muscle spasms
• confused breathing
Constipation
• rash
• sinusitis
• Headache
• Dehydration
• dyspepsia
• Abdominal pain
• vomiting
• loss of appetite
• cough
• fever
• stomatitis
• dizziness
• Urinary tract infection
• Pneumonia
• petechiae
• Arthralgia
• Nose bleed.
Comments
Post a Comment